A £1bn take-private deal for one of Britain's biggest private hospital operators dominated healthcare news, while smaller-cap names delivered a run of commercial milestones, from a digital pharmacy group's surging revenue run rate to a skincare licensing deal and a fresh US regulatory approval for AstraZeneca. Across the sector, dealmaking and organic growth stories both pointed to consolidation and commercial validation as the themes of the day.
Spire Healthcare agrees £1.03bn takeover by Toscafund-led consortium
Spire Healthcare Group (LSE:SPI) has agreed to a recommended cash takeover by Tulip UK Bidco, a vehicle backed by a consortium including Toscafund Asset Management, THCP Advisory (Three Hills) and Ares Management, in a deal that values the hospital operator's equity at approximately £1,026.5m. Shares in Spire rose to 245.5p, up 3.15% on the day, as the market absorbed an offer that ends months of speculation following the board's strategic review launched last September. Spire runs 38 hospitals and more than 55 clinics across England, Wales and Scotland, treating over 1.36m patients in 2025 and holding the largest UK market share by volume in knee and hip operations.
The 250p-per-share offer implies an enterprise value of approximately £2,307.6m, or 8.6 times adjusted EBITDA for the year to 31 December 2025, and represents a 66.2% premium to Spire's 150.4p closing price on 13 May, the day before the possible offer was first flagged. Rothschild & Co canvassed more than 60 potential acquirers over eight months, with Tulip the only party to table a formal proposal the board deemed attractive enough to pursue. Shareholders holding roughly 53.4% of Spire's issued share capital, including Mediclinic Jersey, Harwood Capital Management and Richard Griffiths, have given irrevocable undertakings to support the deal, and an alternative loan-note rollover option, capped at 28m shares, is available but not recommended by the board.
"The Cash Offer of 250p per share was higher than all other formal proposals received during this process, and provides certain value in cash today for Spire Shareholders," said Richard Griffiths, Chair.
The deal would remove one of the UK's largest listed private healthcare operators from public markets at a moment when investor appetite for hospital assets has clearly hardened, an 8.6-times EBITDA multiple and a two-thirds premium signal that private capital sees more value in Spire's NHS-adjacent, elective-care franchise than the public market had been pricing in. With over half the register already locked in, the path to completion looks clear bar regulatory and court process, and the transaction sets a fresh benchmark valuation for UK private hospital groups that rivals and their boards will now be measured against.
Futura Medical retail offer oversubscribed, raise upsized to £200,000
Futura Medical (AIM:FUM) upsized its retail share offer to £200,000 after the tranche closed significantly oversubscribed, even as its shares fell 20.863% to 0.22p on the day. The AIM-listed maker of Eroxon, the over-the-counter topical gel for erectile dysfunction, had originally targeted £150,000 from the retail tranche run on the BookBuild platform; the offer now sees 100m new shares issued at 0.2p each, with applicants scaled back proportionately based on existing shareholdings and application size.
The retail tranche forms part of a wider capital raise combining a placing, conditional placing, conditional subscription and retail offer that together will raise approximately £1.8m before expenses, extending the company's cash runway into February 2027.
Strong retail demand for a heavily discounted raise underscores continuing shareholder support even as the stock trades at fractions of a penny, but the scale of the dilution and the sharp share-price fall highlight how thin the company's financial cushion has become as it works through a formal sale process alongside the fundraise.
MedPal AI hits £28m annualised run rate as New Health revenue jumps 809%
MedPal AI (AIM:MPAL), the AI-native digital health and pharmacy group, said its annualised revenue run rate reached approximately £28m in August, up sharply from £8.6m in July and £5m in June, sending shares up 14.423% to 5.95p. New Health, the group's GLP-1 weight management clinic that began marketing only in July, generated £1.83m in August from 14,487 orders, an increase of 809% on July's £201,203 and a leap from just £15,496 in June.
On an annualised basis New Health alone is now running at roughly £21.9m, having attracted more than 16,000 purchasing customers since its June launch, growth the group said has come entirely through organic trading rather than acquisition. "August was the month it all came together," said Jason Drummond, Founder, adding of the group's cross-selling potential: "One customer, potentially multiple recurring revenue streams. This is what the Health OS was built for." MedPal's other divisions span NHS prescription dispensing through robotic hubs generating gross margins above 27%, and care homes served via its eMARx medication records business.
The speed of New Health's ramp, from under £16,000 to nearly £1.9m of monthly revenue in two months, suggests the GLP-1 weight-management market remains far from saturated for well-positioned digital entrants, and gives MedPal a rapidly scaling growth engine to sit alongside its steadier NHS dispensing base.
Incanthera signs exclusive cream supply deal with LED skincare maker iSmart
Incanthera (LSE:INC) has signed an exclusive bundled distribution agreement with iSmart Developments to supply bioactive creams for use alongside iSmart's LED skincare devices, a deal the dermatology and oncology technology developer said delivers its maiden contracted recurring sales revenue. Shares jumped 33.01% to 1.64p on the news. iSmart manufactures LED brands including Omnilux and faceLITE, shipping roughly 1m devices annually into markets including the US and Australia, and has recently secured FDA clearance for its five-wavelength 5G mask.
The agreement carries contracted annual minimum order quantities tied to iSmart's existing device sales volumes, and a split-face consumer trial run by iSmart found all participants rated the cream-plus-LED side improved versus baseline, with 87% reporting smoother, better-hydrated skin than with the mask alone, though the study was not fully powered for efficacy and a larger three-arm trial is planned. "Our new partnership with iSmart underscores the value of our skincare IP and formulation expertise and brings together our bioactive formulation capabilities with a highly complementary commercial partner with genuine global scale and reach," said Stuart Robertson, Chief Executive.
Landing a first recurring-revenue contract marks a meaningful shift for Incanthera from technology development toward commercial delivery, and the tie-up with a device maker shipping at scale into the US and Australia gives the group a distribution route it has previously lacked. "With commercial momentum now building and a clear strategy in place, I believe the business is firmly on the right path to deliver sustainable growth over the medium term," Robertson added.
Ondine's Steriwave piloted at Mexico's largest private hospital network
Ondine Biomedical (OBI) has signed a commercial deal with Hospital Ángeles to pilot its Steriwave nasal photodisinfection treatment at two flagship Mexican hospitals, following positive Phase 3 results. Shares edged up 0.44% to 11.3p on the news.
The pilot gives Ondine a foothold with Mexico's largest private hospital network, a significant reference customer as the company looks to expand Steriwave's commercial footprint beyond its existing markets on the back of trial data supporting its infection-prevention case.
AstraZeneca wins US approval for Etcamah in breast cancer
AstraZeneca (LSE:AZN) has secured FDA clearance for Etcamah, an oral selective estrogen receptor degrader, to be paired with a CDK4/6 inhibitor for HR-positive breast cancer patients who develop a resistance mutation before their disease progresses. Shares ticked up 0.283% to 12,040p.
The approval extends AstraZeneca's oncology franchise into a defined resistance-mutation patient population, giving clinicians an option to intervene before disease progression is confirmed and reinforcing the group's position in a breast cancer treatment market it has invested heavily to lead.
4basebio expands DNA manufacturing for personalised medicine
4basebio (4BB), the Cambridge-based synthetic DNA specialist, has upgraded its high-quality and cGMP operations to support smaller, patient-specific batches for personalised mRNA medicines. Shares were broadly flat, up 0.12% to 475.55p.
The capacity upgrade positions 4basebio to serve a growing segment of drug developers moving toward individualised mRNA therapies, where manufacturing runs are smaller and more frequent than for conventional bulk production, a shift that could open new revenue lines as personalised medicine programmes advance through clinical development.
